Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

StatusEnrolling by Invitation
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Mar 2027 → Mar 2028
See other at-risk trials from Texas Christian University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 2027 to Mar 2028 Show 4 more changesShow less
    • Trial status changed: Recruiting → Enrolling by Invitation
    • Study completion pushed from Mar 2027 to Jun 2028
    • Start date changed from estimate of Oct 2026 to Oct 22, 2026
    • Site details revised
  2. Start date: Jun 2026 to Oct 2026
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 11 of 11 entries
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.
Trial Details
NCT Number NCT07688720
Lead Sponsor Texas Christian University
Collaborators: Spark Biomedical, Inc.
Conditions
(from sponsor)		 Perimenopause, PMDD
Related terms Premenstrual Dysphoric Disorder
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov